Abstract
Background and Objectives Respiratory syncytial virus (RSV) is responsible for most cases of acute viral bronchiolitis (AVB) in childhood. The association of factors such as RSV subtype, viral load, and viral coinfection with severe disease is controversial. The objective is to describe the viral load dynamics of RSV in children under 2 years with AVB, including the first viral load, peak viral load, viral decay, and any possible association with severe disease.
Methods 73 inpatients with AVB and confirmed RSV infection were included. Viral load was obtained through nasal swab samples daily during hospitalization and weekly after discharge until absence of detection.
Results 44 of the patients were male, the mean age was 5.76 months, and comorbidities were found in 15 (20.5%) of the patients. 54 (74%) of the patients had the peak viral load between the 4th and the 7th day of symptom onset. The mean duration of viral detection was 12.5 days. There was no association between the first and peak viral load with markers of severe disease. However, association was found between viral persistence exceeding 10 days and the following factors: longer hospitalization period (p=0.009), length of ventilation support (p=0.044), length of invasive mechanical ventilation (p=0.035), prolonged requirement of nutritional support (p=0.038), and a longer course of antibiotic treatment (p=0.024). Age was inversely correlated with most of the severity outcomes.
Conclusion Despite the lack of association between RSV viral load values and disease severity, prolonged viral shedding was associated with several adverse outcomes, which can contribute to a better understanding of RSV disease, particularly as several interventions are anticipated to become available in the coming years.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of UNIVERSIDADE FEDERAL DE SAO PAULO gave ethical approval for this work under N. 3.009.916 - CEP/UNIFESP n. 1082/2018 Consent was given from participants legal representatives to take part in the present study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
